Abstract
B UCILLAMINE is a new slow-acting antiinflammatory drug developed in Japan l with a chemical structure similar to that of D-penicillamine. The therapeutic effect of bucillamine is believed to be due to the reduction of serum levels of immunoglobulin and rheumatoid factor and the increase in suppressor T cells in patients with rheumatoid arthritis (RA).2 The nephropathies associated with D-penicillamine in patients with RA include membranous glomerulonephritis (MGN), minimal change disease, necrotizing glomerulonephritis, and crescentic glomerulonephritis. The nephropathies of bucillamine may be similar to that of D-penicillamine. This report describes a patient who had rapidly progressive glomerulonephritis (RPGN) following treatment with bucillamine. The renal biopsy specimen had fibrinoid necrosis, . cellular crescents, and adhesions. The variability of bucillamine-associated nephropathy is discussed.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
